文献速递慢性静脉疾病

热消融与非热消融治疗大隐静脉的对比研究

Thermal versus nonthermal ablation for treatment of great saphenous veins in patients with lower extremity superficial venous disease.
PubMed 文献 · J Vasc Surg Venous Lymphat Disord · 2026-06-23

两组均与临床改善相关,但非热消融在症状缓解和功能恢复方面可能具有优势。

要点

  • 非热消融组CEAP分级从C3改善至C1或C0的比例更高(8% vs 6%)。
  • 非热消融组疼痛从重度改善至轻/中度的比例更高(3% vs 2%)。

核心结论

  • 热消融与非热消融均与慢性静脉疾病的临床改善相关,但非热消融在CEAP分级和疼痛改善方面更优。

研究设计与样本

  • 回顾性队列研究,数据来自血管质量倡议静脉曲张登记库,纳入2014至2026年接受单侧大隐静脉干消融的成人患者,最终分析14277例患者共17504次手术。

主要发现

  • 非热消融组患者年龄更大(61岁[48-70] vs 58岁[46-68],P<.0001),白种人比例更高(85% vs 79%,P<.0001)。
  • 热消融组医院内手术比例更高(34% vs 28%,P<.0001),预防性抗凝使用率更高(低分子肝素9% vs 6%,P<.0001;普通肝素3% vs 1%,P<.0001)。
  • 热消融组多麻醉模式使用率更高(55% vs 17%,P<.0001),区域/肿胀麻醉使用率更高(35% vs 4%,P<.0001)。
  • 热消融组膝上大隐静脉治疗比例更高(89% vs 78%,P<.0001),静脉直径更大(7.3[6.0-9.1] mm vs 6.0[4.0-8.0] mm,P<.0001)。

临床怎么用

  • 对于大隐静脉干反流患者,非热消融可能减少感觉异常并改善CEAP分级和疼痛,尤其适用于高龄或追求更好症状缓解的患者。

局限性

  • 回顾性研究设计,39%患者因缺失消融技术、侧别或干静脉状态数据被排除,可能存在选择偏倚。
  • 非热消融组与热消融组在年龄、种族、静脉直径和麻醉方式等方面存在基线差异,可能影响结果比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chronic venous disease is a prevalent condition that significantly impacts the quality of life of affected patients. In the last 20 years, minimally invasive treatments have become widespread and have typically been classified into thermal or nonthermal ablative techniques. However, few studies have evaluated the efficacy of these interventions, with limited comparative data available with respect to quality of life. METHODS: This was a retrospective cohort study of adults undergoing thermal or nonthermal ablation of unilateral, great saphenous vein (GSV)-truncal veins, identified from the Vascular Quality Initiative Varicose Vein Registry, from 2014 to 2026. Patients with nontruncal, bilateral, or non-GSV-treated veins were excluded. The primary outcome of interest and comparator was long-term quality-of-life outcomes. Fisher exact and Mann-Whitney tests were used to compare categorical and continuous variables. RESULTS: A total of 23,247 patients were analyzed. Ultimately, 14,277 patients undergoing 17,504 procedures met inclusion criteria, with 39% (n = 8970) of patients failing to meet criteria because of missing procedural data regarding ablation technique, laterality, or truncal vein status. Eighty-three percent of procedures were thermal ablations (n = 14,481) compared with 3023 (17%) nonthermal ablations. Nonthermal ablation patients tended to be older (61 [48-70 years vs 58 [46-68] years; P < .0001) and white (85% vs 79%; P < .0001). A higher proportion of thermal ablations occurred in hospitals (34% vs 28%; P < .0001) compared with ambulatory/office-based settings. Furthermore, thermal ablation patients differed from nonthermal ablation patients with respect to prophylactic procedural anticoagulation utilization (low-molecular-weight heparin: 9% vs 6%; P < .0001 and unfractionated heparin: 3% vs 1%; P < .0001) and rates of multiple anesthetic modalities (55% vs 17%; P < .0001) and regional/tumescent (35% vs 4%; P < .0001) utilization. Thermal patients were more likely to have above-knee GSV (89% vs 78%; P < .0001) and a larger diameter vein (7.3 [6.0-9.1] vs 6.0 [4.0-8.0] mm; P < .0001) treated. Patients in the nonthermal group had lower rates of paresthesia in the treated extremity (3% vs 1%; P = .0003) and were more likely to have improvements in Clinical, Etiology, Anatomy, and Pathophysiology scores from C3 to C1 or C3 to C0 (8% vs 6%; P < .0001). Nonthermal patients were also more likely to have pain improvements from severe to mild/moderate (3% vs 2%; P = .0008). CONCLUSIONS: Thermal and nonthermal ablations were both associated with clinical improvement in chronic venous disease. However, patients treated with nonthermal ablations demonstrated greater improvement in Clinical, Etiology, Anatomy, and Pathophysiology class and pain improvement from severe to mild or moderate. These findings suggest a potential therapeutic advantage in symptom resolution and functional recovery with nonthermal ablative techniques. Further investigation regarding long-term quality-of-life measures following nonthermal ablation is warranted.

来源:J Vasc Surg Venous Lymphat Disord,查看原文。版权归原作者所有。

引用

  1. Katukota A, Fassler M, Scali S, et al. Thermal versus nonthermal ablation for treatment of great saphenous veins in patients with lower extremity superficial venous disease. J Vasc Surg Venous Lymphat Disord. 2026. PMID: 42336102. doi:10.1016/j.jvsv.2026.102550

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。